Skip to main content

James Johnson Comment On Regulatory Notice 22-08

I have been using leveraged and inverse ETFs with great success for 12 years, with proof of performance results far greater than S&P 500. I have an MBA from Tulane, but my trading education began by studying with Steve Lescarbeau, featured in Market Wizards by Jack Schwager. My experience and methods of analysis of selecting appropriate funds are far beyond the many authors of articles about leveraged funds, the vast majority panning them, and viewing them through an ultra short term prism. To be blunt, they have missed the boat.

Adam Hill Comment On Regulatory Notice 22-08

Dir Sir/Madam It is none of your business what investments are right for myself and my family. I am an adult capable of making my own decisions and living with the consequences of those decisions. Furthermore there should be no restrictions on the types of investments available to the general public. All investments available to the "privileged few" should be available to the general public as well. The general public should not be subject to any restrictions or special processes prior to investing in public securities regardless of their leveraged or inverse nature.

Brian Dolan Comment On Regulatory Notice 22-08

I need the ability to freely invest in whatever is best for my family and our future. Increased regulations that make it more complicated or restrictive is unfair to individual investors. I can understand leveraged and inversed funds and should be able to invest in them if I choose. The term "comolex products" used in the proposed regulation is very vague. Regulators shouldn't be able to decide that I can't invest in something.

David Jones Comment On Regulatory Notice 22-08

Inverse fund products provide a necessary alternative to shorting an over-valued security while minimizing the risk with a direct short of a security. Additionally, leveraged products are an alternative to margining ones account, which can lead to margin calls. Lastly, most brokerages have internal controls to limit individual's exposure to any risks that may be associated with leveraged products; additional external regulations are not necessary.